148 related articles for article (PubMed ID: 19811110)
1. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
Harris KC; Anis AH; Crosby MC; Cender LM; Potts JE; Human DG
Can J Cardiol; 2011; 27(4):523.e11-5. PubMed ID: 21664100
[TBL] [Abstract][Full Text] [Related]
7. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
9. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
Committee on Infectious Diseases
Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
Sunnegårdh J
Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
[TBL] [Abstract][Full Text] [Related]
13. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
14. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
15. Changing costs and the impact on RSV prophylaxis.
Smart KA; Paes BA; Lanctôt KL
J Med Econ; 2010; 13(4):705-8. PubMed ID: 21087075
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
Meberg A; Bruu AL
Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
[TBL] [Abstract][Full Text] [Related]
17. Health economics and RSV.
Carbonell-Estrany X; Lázaro y de Mercado P
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
[TBL] [Abstract][Full Text] [Related]
18. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
Saji T; Nakazawa M; Harada K
Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ; Wittenberg W; Lebmeier M
Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
